Cooperation Agreement Concluded between BioKangtai and Biotis
-- Indicating Technology Transfer of the World's First Dual-carrier 13-valent Pneumococcal Conjugate Vaccine toIndonesia SHENZHEN, China, April 7, 2023 /PRNewswire/ -- On the morning of April 5, Beijing Minhai Biotechnology Co., Ltd. (hereinafter referred to as "BioMinhai"), a wholly-owned subsi...
Licensing and Agency Agreement Signed between Beijing Minhai (Biokangtai) and Phil. Pharmawealth, Inc.
Marks the First Entry of Biokangtai's 13-valent Pneumococcal Vaccine into Southeast Asian Market SHENZHEN, China, Aug. 31, 2022 /PRNewswire/ -- On August 30, Beijing Minhai Biotechnology Co., Ltd. held a signing ceremony with Phil. Pharmawealth, Inc. for their cooperation in jointly promoting th...
BIOKANGTAI Signs a Cooperation Agreement with the Largest Importer of Parenteral Products in Philippines
SHENZHEN, China, March 21, 2022 /PRNewswire/ -- On March 17, 2022, Shenzhen Kangtai Biological Products Co., Ltd signed a framework agreement with Phil.PharmaWealth Inc., the largest importer of Parenteral Products in Philippines, and both parties reached an agreement on jointly promoting the reg...
Kangtai Adenovirus Vector COVID-19 Vaccine (KCONECAVAC) Exported for the First Time
SHENZHEN, China, Nov. 19, 2021 /PRNewswire/ -- At 3 a.m. on November 19, the first batch of more than 4 million doses of adenovirus vector COVID-19 vaccines produced by Shenzhen Kangtai Biological Products Co., Ltd. will depart from Shenzhen Bao'an International Airport and will arrive in Jakarta...
BioKangtai's adenovirus vector COVID-19 vaccine obtained EUA in Indonesia
SHENZHEN, China, Nov. 3, 2021 /PRNewswire/ -- As reported by Indonesian National Agency of Drug and Food Control (BPOM), BPOM grants the Emergency Use Authorization (EUA) for COVID-19 Vaccine (ChAdOx1-S[recombinant])/KconecaVac manufactured by Shenzhen Kangtai Biological Products Co., Ltd. It is ...
Biokangtai: Recombinant COVID-19 Vaccine(Adenovirus Vector) licensed for manufacturing, which actively promotes vaccine export and improves vaccine accessibility
SHENZHEN, China, Sept. 8, 2021 /PRNewswire/ -- The other day Shenzhen Kangtai Biological Products Co., Ltd. announced that the company and AstraZeneca signed the "Amendment 1 to License Agreement". In addition to authorizing BIOKANGTAI to commercialize its Recombinant COVID-19 Vaccine(Adenovirus ...
BIOKANGTAI COVID-19 Vaccine Approved for Phase III Clinical Trial in the Philippines
SHENZHEN, China, Aug. 2, 2021 /PRNewswire/ -- On July 30, Shenzhen Kangtai Biological Products Co., Ltd. (BIOKANGTAI) was approved by the Philippine Food and Drug Administration (PFDA) to launch the phase III clinical trial of its independently developed Inactivated COVID-19 Vaccine (Vero cells) ...
Phase III Clinical Trial of BIOKANGTAI COVID-19 Vaccine Initiated in Malaysia
SHENZHEN, China, June 22, 2021 /PRNewswire/ -- On June 21, local time, phase III clinical fieldwork of the Inactivated COVID-19 Vaccine (Vero cells) independently developed and manufactured by Shenzhen Kangtai Biological Products Co., Ltd. was officially initiated inMalaysia, and the first batch ...
